Pfizer (PFE) Tops Q2 EPS by 33c, Reaffirms FY22 Comirnaty and Paxlovid Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pfizer (PFE) Earnings Growth 'Underappreciated' - Cantor Fitzgerald
July 28, 2022 1:32 PM EDTPfizer (NYSE: PFE) topped estimates when it reported earnings for the second quarter premarket Thursday.
The drugmaker reported a profit of $2.04 per share, $0.33 better than the analyst estimate of $1.71. Revenue for the quarter came in at $27.7 billion versus the consensus estimate of $25.26... More
